Physician profile

Max Egers

Washington, DC

NPI 1598344707

$414.10

in general payments reported to CMS, 2019-2025

6 companies · $414 in 2025

The $414 reported for 2025 was more than what 75% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$414.10

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Teleflex LLC $168.42 2025 Manta
Pfizer INC. $124.49 2025
Medtronic, INC. $47.19 2025 Cobalt Dr Mri Surescan, Mycarelink
Novo Nordisk INC $33.99 2025 Wegovy
Kestra Medical Technology Services, INC. $22.47 2025 Assure Wcd
Terumo Medical Corporation $17.54 2025 Metacross Otw

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Max Egers

$414.10

in general payments reported 2019-2025

Years
2025
Top company
Teleflex LLC
Context
The $414 reported for 2025 was more than what 75% of providers received nationally.

https://glasscript.com/doctor/11957439/max-egers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.